Advertisement

Related Videos

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Amit Sanyal, MD: A Clinician’s Perspective

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Peter Clark, MA, MD, FRCP: A Payer Perspective

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Advertisement

Advertisement




Jan
11
Today In Oncology
Flipped Nivolumab/Ipilimumab Dosing Improves Outcomes in Advanced Melanoma
In Head-to-Head Comparison, Fixed-Duration Treatment Noninferior to Continuous for Previously Untreated CLL
Researchers Create Immune Cell Atlas of Bone Marrow in Patients With Multiple Myeloma
Small Study Examines Potential of Artificial Saliva in Patients With Head and Neck Cancer
Are Food Preservatives Linked to Increased Cancer Risk
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo